Compare Chipotle Mexican Grill, Inc. (CMG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chipotle Mexican Grill, Inc. vs TG Therapeutics Inc — how do they compare? Chipotle Mexican Grill, Inc. trades at $32.75 (market cap $40.49B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 5.3× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Chipotle Mexican Grill, Inc. nearer its low. Which is the better fit depends on your goals.
| CMG | TGTX | |
|---|---|---|
Market Cap | $40.49B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $44.04 | $59.06 |
52-Week Low | $28.17 | $26.94 |
Enterprise Value | $45.24B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chipotle Mexican Grill (CMG) trades at $32.615, up 1.48% today, but faces headwinds from recent food safety concerns linked to salmonella outbreaks. The stock's technical outlook is bearish, with moving averages signaling selling pressure. Fundamentally, the company reported strong revenue growth to $11.93B in 2025 and a net income margin of 11.42%, though earnings face compression from rising costs. Recent news highlights ongoing litigation investigations and promotional efforts to boost customer engagement.
The investment outlook is mixed; analyst consensus remains bullish with a $42.17 price target, but near-term risks from food safety issues and margin pressures could limit upside. Long-term growth prospects are supported by consistent revenue increases, but investors should monitor resolution of health concerns and cost management.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
